Skip to main content
SKYE logo

SKYE · Skye Bioscience, Inc. · Executive Compensation

Track SKYE — free
$1.02 -0.01 (-1.36%) Play latest call Q4 2025 earnings call transcript
Market Cap
$4.56M
Shares
4.42M
Volume · Nov 19 12.7K Avg daily vol (62 sessions) 84.15K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Punit Dhillon $1,361,831
Kaitlyn Arsenault $888,589
Tu Diep $875,939
Fiscal 2024
Executive Total
Punit Dhillon $6,139,625
Kaitlyn Arsenault $2,266,825
Tu Diep $2,207,168
Fiscal 2023
Executive Total
Punit Dhillon $1,807,338
Kaitlyn Arsenault $1,270,290
Tu Diep —
Fiscal 2022
Executive Total
Punit Dhillon $668,481
Kaitlyn Arsenault $469,087

Executive changes

Person Change Filed
Punit Dhillon Appointed 2026-09-11
John P. Sharp
“Mr. Sharp’s departure is not the result of any disagreement with the Company’s independent auditors or the Company on any matter relating to the Company’s financial statements, internal control over financial reporting, operations, policies or practices.”
Resigned 2026-09-11
Dr. Cliff Jones Appointed 2026-08-14
Dr. Mei-Lun Wang Appointed 2026-08-14
Dr. Caroline Phillips Appointed 2026-08-14
Peter Collum Appointed 2026-08-14
Lisa Anson Appointed 2026-08-14
Tu Diep Resigned 2026-08-14
Punit Dhillon Resigned 2026-08-14
John P. Sharp Appointed 2026-04-03
Punit Dhillon Appointed 2026-02-20
Paul Grayson Appointed 2024-10-29
Puneet S. Arora, MD, MS, FACE Appointed 2024-09-04
Keith Ward, PhD
“Dr. Ward and Dr. Tyle's decision to resign from the Board is not as a result of any disagreement with the Company concerning any matter relating to its operations, policies or practices.”
Resigned 2024-07-03
Praveen Tyle, PhD
“Dr. Ward and Dr. Tyle's decision to resign from the Board is not as a result of any disagreement with the Company concerning any matter relating to its operations, policies or practices.”
Resigned 2024-07-03
Karen L. Smith MD, PhD, MBA, LLM Appointed 2024-07-03
Margaret Dalesandro
“Dr. Dalesandro’s decision to resign from the Board is not as a result of any disagreement with the Company concerning any matter relating to its operations, policies or practices.”
Resigned 2024-03-04
Annalisa Jenkins Appointed 2024-03-04
Paul Grayson Appointed 2023-08-21
Andy Schwab Appointed 2023-08-21
Paul Grayson Appointed 2023-08-21
Andrew Schwab Appointed 2023-08-21
Dr. Deborah Charych, Ph.D. Appointed 2023-02-16
Bobby Rai
“Mr. Rai's resignation as a director was to focus on other commitments and is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2023-02-16
Bobby Rai Appointed 2023-01-06

Leadership

Key facts CIK 1516551 CUSIP 83086J309 13F (30d) 32 filings 29 filers Visit website Investor relations